The Economist

Everyone wants to be an influencer these days. That’s good for companies, but bad for creators.

Microsoft and OpenAI are already in the process of renegotiating the terms of their lucrative relationship.

First, drugs like Ozempic tackled diabetes. Then it was obesity. Now it’s cardiovascular and kidney disease, with Alzheimer’s and addiction on the horizon. The possibilities truly are endless.

The contest for global smartphone dominance gets interesting.

However much you want to keep politics out of business, politics has other plans for you.

Lots of reforms would benefit America’s democracy. Giving billionaires more influence over the outcome of elections is not one of them. 

Their efficiency rates far exceed those of conventional silicon panels and they can also be made cheaply from easily obtainable materials. 

The famous Big Mac index is a light-hearted gauge of whether currencies are at their ‘correct’ level and a useful way of comparing international salaries.

America’s economy is bigger and better than ever, but its politics gets more poisonous by the day. Will this be the undoing of the most important economy in the world?

Gaza’s mastermind of mayhem is dead. A ceasefire may be alive again

Entrepreneurs and venture capitalists are betting that generative AI can make customer service less awful. 

It is setting standards for everything from 6G to quantum computing.

Elon Musk is serving up a vision of an autonomous Cybercab so cheap that it will serve as ‘individualised mass transit’. But his promises, like many Hollywood movies, are long on bombast and short on reality.

If SpaceX can land and reuse the most powerful rocket ever made what can’t it do?

Israel’s strongest sector has proven resilient in the past, but it is now facing serious pressure.